Progress on haptoglobin and metabolic diseases

被引:26
|
作者
Wan, Bao-Nian [1 ]
Zhou, Shi-Gao [1 ]
Wang, Miao [1 ]
Zhang, Xiao [1 ]
Ji, Guang [2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept TCM Demonstrat, Shanghai 200032, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Inst Digest Dis, Longhua Hosp, 725 Wanping South Rd, Shanghai 200032, Peoples R China
关键词
Haptoglobin; Polymorphism; Metabolic diseases; Simple obesity; Inflammation; CD163; ADIPOSE-TISSUE; OBESITY; ASSOCIATION; PLASMA;
D O I
10.4239/wjd.v12.i3.206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haptoglobin (Hp) is an acidic glycoprotein, existing in the serum and other body fluids of human beings and a variety of mammals. Hp is produced in the liver, white adipose tissue, and the kidney. The genetic polymorphisms and different phenotypes of Hp have different biological functions. Hp has antibacterial, antioxidant, and angiogenic effects and is associated with multiple diseases including simple obesity, vascular complications of diabetes mellitus, nonalcoholic fatty liver disease, hypertension, blood diseases, autoimmune diseases, and malignant tumors. Hp also participates in many life activities, indicating the importance of Hp in further studies. Previously, we found that the expression of serum Hp changed after treatment of simple obesity patients in clinical trials. However, the specific mechanism of Hp in patients with simple obesity is still unclear. The purpose of this article is to introduce recent research progress on Hp, emphasizing the relationship between Hp and the development of metabolic disease, which will improve the understanding of the functions of Hp underlying metabolic diseases and discuss future research directions.
引用
收藏
页码:206 / 214
页数:9
相关论文
共 50 条
  • [11] Lysosome/lipid droplet interplay in metabolic diseases
    Dugail, Isabelle
    BIOCHIMIE, 2014, 96 : 102 - 105
  • [12] Role of metaflammation as a systemic manifestation of metabolic diseases
    Schaeffler, Andreas
    INNERE MEDIZIN, 2023, 64 (04): : 313 - 322
  • [13] Sensitivity of the Neuroendocrine Stress Axis in Metabolic Diseases
    Cozma, Diana
    Siatra, Panagiota
    Bornstein, Stefan R.
    Steenblock, Charlotte
    HORMONE AND METABOLIC RESEARCH, 2024, 56 (01) : 65 - 77
  • [14] Drug Delivery Strategies for the Treatment of Metabolic Diseases
    Shi, Sanjun
    Kong, Na
    Feng, Chan
    Shajii, Aram
    Bejgrowicz, Claire
    Tao, Wei
    Forokhzad, Omid C.
    ADVANCED HEALTHCARE MATERIALS, 2019, 8 (12)
  • [15] Obstructive Sleep Apnea Syndrome and Metabolic Diseases
    Li, Min
    Li, Xiaoying
    Lu, Yan
    ENDOCRINOLOGY, 2018, 159 (07) : 2670 - 2675
  • [16] The Role of CARD9 in Metabolic Diseases
    Tian, Cheng
    Tuo, Ya-li
    Lu, Yi
    Xu, Chuan-rui
    Xiang, Ming
    CURRENT MEDICAL SCIENCE, 2020, 40 (02) : 199 - 204
  • [17] The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus
    Dalan, Rinkoo
    Liuh Ling, Goh
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 25 (14) : 1502 - 1519
  • [18] Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation?
    An, Jinyang
    Fu, Donghua
    Chen, Ximei
    Guan, Conghui
    Li, Lingling
    Bai, Jia
    Lv, Haihong
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [19] Metabolic Diseases and Periodontitis
    Noack, B.
    Fischer, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (22) : 1155 - 1157
  • [20] Western diets, gut dysbiosis, and metabolic diseases: Are they linked?
    Martinez, Kristina B.
    Leone, Vanessa
    Chang, Eugene B.
    GUT MICROBES, 2017, 8 (02) : 130 - 142